セッション情報

FACO International Workshop

第53回・2015年・京都
FACO International Workshop
FACO International Workshop 11
Breast Cancer
開催回
第53回・2015年・京都

Epithelial paradox: Clinical significance of co-expression of E-cadherin and vimentin in invasive breast cancer

演題番号 : FWS11-1

Yamashita Nami:1、Tokunaga Eriko:2、Inoue Yuka:3、Tanaka Kimihiro:3、Ueo Hiroki:3、Saeki Hiroshi:3、Oki Eiji:3、Maehara Yoshihiko:3

1:Dept of Comprehensive Clinical Oncology, Graduate School, Kyushu University、2:Dept of Breast Oncology, National Hospital Organization Kyushu Cancer Center、3:Dept of Surgery and Science, Graduate School, Kyushu University

Epithelial paradox: Clinical significance of co-expression of E-cadherin and vimentin in invasive breast cancer

Association of CYP2C19*2 and associated haplotypes with lower norendoxifen levels in tamoxifen-treated asian breast cancer patients

演題番号 : FWS11-2

Chowbay Balram:1,2,3、Joanne Lim Siok Liu:1、Sutiman Natalia:2、Muerdter Thomas E.:6,7、Singh Onkar:1、Raymond Ng Chee Hui:4、Yap Yoon Sim:4、Wong Nan Soon:5、Schroth Werner:6,7、Schwab Matthias:6,8

1:Division of Medical Sciences, Laboratory of Clinical Pharmacology, National Cancer Center Singapore、2:Clinical Pharmacology, Singapore Health Services Pte Ltd、3:Clinical Sciences, Duke-NUS Graduate Medical School、4:Medical Oncology, National Cancer Center Singapore、5:OncoCare Cancer Centre, Mount Elizabeth Novena Medical Centre Singapore、6:Clinical Pharmacology, Dr. Margarete Fischer-Bosch Institute、7:University Tubingen Germany、8:Clinical Pharmacology, University Hospital, Tubingen

Association of <i>CYP2C19*2</i> and associated haplotypes with lower norendoxifen levels in tamoxifen-treated asian breast cancer patients

Clinical significance of GPNMB and its association with HER2 in breast cancer

演題番号 : FWS11-3

Futamura Manabu:1、Morimitsu Kasumi:1、Mori Ryutaro:2、Yoshida Kazuhiro:2

1:Dept. of Breast & Molecular Oncology, School of Medicine, Gifu University、2:Dept. of Surgical Oncology, School of Medicine, Gifu University

Clinical significance of GPNMB and its association with HER2 in breast cancer

The role of topoisomerase [IIA] as a predictive factor for response to neoadjuvant anthracyclines based chemotherapy in locally advanced breast cancer

演題番号 : FWS11-4

Gamea Mohamed M.:1,2,3,4、Barakat Ashraf F.:1,2,3,4、Hussein Fatma Z.:1,2,3、Almeldin Mohamed A.:1,2,3

1:chemotherapy, clinical oncology, tanta university、2:chemotherapy, clinical oncology, tanta university、3:chemotherapy, clinical oncology, tanta university、4:chemotherapy, clinical oncology, tanta university

The role of topoisomerase [IIA] as a predictive factor for response to neoadjuvant anthracyclines based chemotherapy in locally advanced breast cancer

Phase Ib dose-escalation study of Eribulin (Eri) in combination with Gemcitabine (GEM) in patients (pts) with metastatic breast cancer (MBC)

演題番号 : FWS11-5

Kashiwaba Masahiro:1、Goto Risa:3、Kondo Naoto:2、Hattori Masaya:2、Iwata Hiroji:2

1:Dpt. of Surgery, Iwate Medical University、2:Dpt. of Breast Oncology, Aichi Cancer Center Hospital、3:Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital

Phase Ib dose-escalation study of Eribulin (Eri) in combination with Gemcitabine (GEM) in patients (pts) with metastatic breast cancer (MBC)

Phase III trial evaluating the addition of bevacizumab to paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: Japanese subgroup data in MERiDiAN study

演題番号 : FWS11-6

Kashiwaba Masahiro:1、Takahashi M:2、Nakagami K:3、Okumura Y:4、Nakayama T:5、Sato N:6、Kanatani K:7、Masuda N:8

1:Iwate Medical University, Morioka, Japan、2:Hokkaido Cancer Center, Sapporo, Japan、3:Shizuoka General Hospital, Shizuoka, Japan、4:Kumamoto City Hospital, Kumamoto, Japan、5:Osaka Medical Center, Osaka, Japan、6:Niigata Cancer Center, Niigata, Japan、7:Chugai Pharmaceutical Co. Ltd, Tokyo, Japan、8:NHO Osaka National Hospital, Osaka, Japan

Phase III trial evaluating the addition of bevacizumab to paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: Japanese subgroup data in MERiDiAN study